Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Introduction: Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Clinical Trials

Study to Compare the Efficacy of Tocilizumab With or Without Glucocorticoid Discontinuation in Rheumatoid Arthritis Participants

Phase 4

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Placebo matched to prednisone
Drug: Prednisone
Biological: Tocilizumab

First Posted Date: 2015-10-09

Last Posted Date: 2019-11-01

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 314

Registration Number: NCT02573012

Locations: 🇫🇷
Hopital Pellegrin; Rhumatologie, Bordeaux, France
🇫🇷
Hopital Cochin; Rhumatologie B, Paris, France
🇫🇷
Hopital Hautepierre; Rhumatologie, Strasbourg, France

and more 36 locations

A Bioequivalence Study of Pegylated Interferon Alfa-2a (PEG-IFN Alfa-2a) Benzyl Alcohol (BA)-Free Formulation Versus PEG-IFN Alfa-2a (Pegasys) Following Subcutaneous Administration

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: PEG-IFN alfa-2a BA-free formulation (Test)
Drug: PEG-IFN alfa-2a market formulation (Reference)

First Posted Date: 2015-10-09

Last Posted Date: 2017-03-13

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 277

Registration Number: NCT02573025

Locations: 🇭🇰
The University of Hong Kong; Pharmacy Clinical Trials, Hong Kong, Hong Kong
🇳🇿
Christchurch Clinical Studies Trust, Christchurch, New Zealand
🇳🇿
Auckland Clinical Studies Limited, Grafton, New Zealand

and more 6 locations

A Study of PEGASYS (Peginterferon Alfa-2a [40KD]) in Patients With Hepatitis B e Antigen (HBeAg)-Negative Chronic Hepatitis B Virus (HBV)

Phase 4

Completed

Conditions: Hepatitis B, Chronic

Interventions: Drug: Peginterferon alfa-2a

First Posted Date: 2015-10-07

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 60

Registration Number: NCT02570191

A Study of Long-Term Rituximab (MabThera) Maintenance Therapy in Participants With Advanced Follicular Lymphoma

Phase 3

Completed

Conditions: Lymphoma, Follicular

Interventions: Drug: Rituximab

First Posted Date: 2015-10-07

Last Posted Date: 2015-12-10

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 124

Registration Number: NCT02569996

A Study of Enfuvirtide (Fuzeon) in Patients With Advanced Human Immunodeficiency Virus-1 (HIV-1) Infection

Phase 4

Completed

Conditions: HIV Infections

Interventions: Drug: enfuvirtide

First Posted Date: 2015-10-06

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 6

Registration Number: NCT02569502

A Study of Epoetin Beta (NeoRecormon) in Predialysis Patients With Renal Anemia

Phase 4

Completed

Conditions: Anemia

Interventions: Drug: Epoetin Beta

First Posted Date: 2015-10-06

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 58

Registration Number: NCT02569515

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

Phase 2

Active, not recruiting

Conditions: Pancreatic Cancer
Adult Solid Tumor
Lymphoma, Large-Cell, Anaplastic
Primary Brain Tumors
Sarcomas
Breast Cancer
Non-Small Cell Lung Cancer
Ovarian Cancer
Papillary Thyroid Cancer
Salivary Gland Cancers

Interventions: Drug: Entrectinib

First Posted Date: 2015-10-05

Last Posted Date: 2025-05-30

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 534

Registration Number: NCT02568267

Locations: 🇺🇸
Oregon Health & Science Univ, Portland, Oregon, United States
🇫🇷
Institut De Cancerologie De L'ouest - Rene Gauducheau - Biology, Saint Herblain, France
🇫🇷
Institut Claudius Regaud, Toulouse, France

and more 124 locations

A Study of Capecitabine (Xeloda) in Patients With Metastatic Colorectal Cancer

Phase 4

Completed

Conditions: Colorectal Cancer

Interventions: Drug: Capecitabine

First Posted Date: 2015-10-02

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 28

Registration Number: NCT02567331

A Study of MIRCERA in Participants With Chronic Kidney Disease Stage 3-4 and Not on Dialysis

Completed

Conditions: Anemia

Interventions: Other: MIRCERA

First Posted Date: 2015-10-02

Last Posted Date: 2016-02-15

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 144

Registration Number: NCT02567188

A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC)

Phase 1

Completed

Conditions: Carcinoma, Hepatocellular

Interventions: Drug: RO7070179

First Posted Date: 2015-10-01

Last Posted Date: 2018-02-15

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 9

Registration Number: NCT02564614

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸
Indiana University, Indianapolis, Indiana, United States
🇺🇸
Laura and ISAAC Perlmutter Cancer Center at NYU Langone., New York, New York, United States

and more 4 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy